menu
Erectile Dysfunction Market is estimated to be US$ 10.14 Billion in 2030 at a CAGR 6.20% during the forecast period
Erectile Dysfunction Market is estimated to be US$ 10.14 Billion in 2030 at a CAGR 6.20% during the forecast period
The report " Global Erectile Dysfunction Market, By Therapy Type (Drug Therapy and Device Therapy), and By Region (North America, Asia Pacific, Europe, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2030”

Erectile Dysfunction Market accounted for US$ 5.54 billion in 2020 and is estimated to be US$ 10.14 billion by 2030 and is anticipated to register a CAGR of 6.2%. Erectile dysfunction (ED), also called impotence, is that the sort of sexual dysfunction during which the penis fails to become or stay erect during sexual intercourse. It’s the foremost common sexual problem in men. Through its connection to self-image and to problems in sexual relationships, male erecticle dysfunction can cause psychological harm. In about 80% of cases, physical causes are often identified.These include cardiovascular disease; diabetes mellitus; neurological problems, like those following prostatectomy; hypogonadism; and drug side effects. About 10% of cases are psychological impotence, caused by thoughts or feelings;here, there's a robust response to placebo treatment. The term male erecticle dysfunction isn't used for other disorders of erection, like priapism. 

The report " Global Erectile Dysfunction Market, By Therapy Type (Drug Therapy and Device Therapy), and By Region (North America, Asia Pacific, Europe, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2030

Key Highlights:

·         In 2019, Boston Scientific (NYSE:BSX) recently launched what it describes as a durable, natural-feeling implant to treat erectile dysfunction.

·         In 2021, -Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced positive topline results from a Phase 3 study evaluating the safety and efficacy of ULTOMIRIS (ravulizumab-cwvz) in adults with generalized myasthenia gravis (gMG).

Analyst View:

High incidence and increase in the occurrence of erectile dysfunction are expected to boost the global market growth within the forecast period. As per to the research led by the U.S, approximately 50 million men experience erectile dysfunction in the U.S. The incidence rate of erectile dysfunction has augmented from 5% (among men 40 years old) to 15% (among those 70 years old). This occurrence rate of erectile dysfunction is projected to upsurge owing to the fact such as a rise in the aged population and increase in the prevalence of diseases such as cardiovascular diseases, hypercholesterolemia, and diabetes, causing the normal erectile functioning. The rising threat of sexually transmitted diseases (STD), constricting of insurance coverage for erectile dysfunction therapy, increasing risks of counterfeit medications, and the existence of social disgrace in developing countries could limit the market growth.

Before purchasing this report, request a sample or make an inquiry by clicking the following link:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/141

 

Key Market Insights from the report:

The Global Erectile Dysfunction Market accounted for US$ 5.54 billion in 2020 and is estimated to be US$ 10.14 billion by 2030 and is anticipated to register a CAGR of 6.2%. The global erectile dysfunction market has been segmented on the basis of therapy type, and region.

·         By Therapy Type, the market is segmented into Drug Therapy and Device Therapy .

·         By Region, the Global Diabetic Neuropathy Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Competitive Landscape:

Key players operating in the global erectile dysfunction market includes Teva Pharmaceutical Industries Limited, Bonro Medical, Endo International Plc., Eli Lilly and Company, Futura Medical, Augusta Medical Systems LLC, Pfizer,Cristalia Produtos Quimicos Farmaceuticos Ltda., Premedon,SK Chemicals, Post-T-Vac Medical, Bayer AG, VIVUS Inc., Boston Scientific Corp.,Zephyr Surgical Implants (ZSI), Apricus Biosciences Inc., and Coloplast A/S.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.